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Case Presentation 
An 8 year-old girl presented with a 3 week history of  
headache, neck stiffness, deafness, fever and vomiting to 
Mulanje Mission Hospital. The child was previously well until 
3 weeks prior to presentation when she started complaining 
of  headache, which was persistent and kept the child awake 
at night. There was also associated intermittent fevers and 
vomiting, especially in the morning. Her mother reported 
that she had been going to several local clinics with the child, 
upon the onset of  the illness where the child was being 
treated for malaria, even though the malaria rapid diagnostic 
tests were negative. As her symptoms were not improving, 
one local clinic decided to refer the child to the Mission 
Hospital. At the Mission Hospital, on initial assessment, 
the child had fever, signs of  meningism and deafness. The 
weight-for-height z-score was ≤3 with a middle upper arm 
circumference (MUAC) of  14.5 cm. 
On initial assessment the child was confirmed HIV-negative 
after three negative antibody rapid tests (Determine™ and 
Unigold™). Subsequent HIV DNA PCR was also done 
which was negative. Cerebrospinal fluid (CSF) analysis was 
as follows: WBC 0-3 x 103/µL, acid fast bacilli negative, 
Gram stain with Gram positive yeast, Indian Ink positive 
and Cryptococcal antigen positive. The hospital did not have 
capacity for performing culture. Based on positive Gram 
stain and Cryptococcal antigen, a diagnosis of  cryptococcal 
meningitis was made, and the child was started on oral 
fluconazole induction phase at 12 mg/kg/day. After the 
initiation of  treatment, the child continued to have severe 
headaches and therapeutic lumbar punctures were done on 
days 1, 5 and 7.  On day 9 there was an improvement on the 
headaches.
After being on fluconazole for 5 weeks child was transferred 
to Queen Elizabeth Central Hospital (QECH), a tertiary 
government referral centre for the Southern Malawi region. 
The reasons for transfer was firstly, for possible access to 
first-line fungicidal therapy, and secondly, for work up of  
possible underlying condition. The family also requested to 
be referred because they could no longer afford to pay for 
treatment at the Mission Hospital.
At QECH, on history the child had no recurrent respiratory 
infections or persistent otitis media, no skin rash or eczema, 
no prior history of  persistent vomiting before this illness, 
no history of  persistent diarrhoea or having bloody stool, 
and no history of  bleeding tendencies. Mother reported 
that child had normal development and no prior history of  
poor balance or abnormal gait. On examination the child 
had a weight of  16 kg, a height of  111.5 cm, with a weight/
height of  -2SD. The child had no dysmorphic features, had 
normal skin (no rash or stigma of  previous skin lesions), 
no telangiectasia, no finger clubbing and had no significant 
lymphadenopathy. On chest examination, the lung fields 
were clear and had normal heart sounds with no murmurs. 
She had a soft and non-tender abdomen with a palpable liver 
of  about 1 cm below the costal margin with no splenomegaly. 
Neurologically child was alert, unable to hear properly, and 
no facial asymmetry. She had normal tone with some tremor 
in the upper limbs and was noticed to have an ataxic gait. 
Tests done at QECH were as follows: FBC: WBC 6.7 x 10³/
µL, RBC 4.07 x 103/µL, haemoglobin 10.4 g/dL, haematocrit 
32.0%, platelets 330 x 10³/µL, total lymphocytes 2.0 x 10³/µL 
(with total CD4 count 705/µL with no percentage available), 
total neutrophils 3.8 x 10³/µL, calcium 1.0 mmol/L, random 
blood sugar 5.4 mmol/L. CSF showed WBC 30 x 103/µL, 
RBC 3040 x 103/µL, polymorphs 70%, lymphocytes 30%, 
no organisms were seen on Gram stain, Indian Ink was 
negative, and there was no growth on culture. 
As the child had persistent neurological signs and symptoms 
as described above, an MRI was done. This showed mild 
hydrocephalus (Figure 1). Given her clinical improvement, 
this was managed conservatively. With the presence of  
hearing deficit, a hearing test was done which showed mild 
to moderate sensory-neural hearing loss on the left ear. 
The child was continued on oral fluconazole (12 mg /kg) 
and was discharged after she had stayed in hospital for 17 
days. She was seen for follow up in clinic 2 months later, 
and at that time her hearing impairment was improving and 
her headache had resolved. Given that no immunodeficiency 
was identified, the child received induction and maintenance 
courses of  oral fluconazole and completed a total of  15 
weeks’ treatment. 
Discussion
Cryptococcal meningitis is the most common central 
nervous system (CNS) fungal infection with high morbidity 
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and mortality.  Globally, approximately 957,900 cases of  
cryptococcal meningitis occur annually, resulting in 624,700 
deaths within 3 months of  infection in 
HIV-infected adults and children1. These occur primarily in 
low-income countries, where health care and resources are 
limited. The incidence of  cryptococcosis in Chinese children 
is 0.016–100 cases/100,000 children2. HIV infection is the 
main risk factor, accounting for 95% of  cases in middle- 
and low-income countries and 80% of  cases in high-income 
countries. The other risk factors include transplant recipients, 
patients with acute leukaemias or lymphomas, and those on 
immunosuppressive therapy including steroids. Cryptococcal 
infection in immunocompetent host is usually attributed to 
Cryptococcus gattii while that in immunocompromised is mostly 
by C. neoformans3,4. While India ink preparation only has a 
sensitivity of  86.1% and specificity of  97.3%5, diagnosis 
of  cryptococcal meningitis can be reliably performed by 
serum cryptococcal latex agglutination titre which has a 
sensitivity of  97-97.8% and specificity of  85.9-100%5, or by 
cryptococcal antigen testing in CSF, which has a sensitivity 
of  100% and specificity of  97.7%, or serum (sensitivity 
100% and specificity 99.5%)5. 
In this case, we did not identify an underlying cause 
for the cryptococcal meningitis5. Diagnosing a primary 
immunodeficiency in our setting is challenging as laboratory 
capacity is limited. We followed a pragmatic approach: 
considering that our patient had reach middle infancy without 
major problems we focused our differential diagnosis on 
partial T-cell deficiencies and with the history and simple 
laboratory tests we evaluated for and confidently excluded 
the most common conditions (DiGeorge Syndrome, Ataxia 
Telangiectasia, Wiskott-Aldrich Syndrome and Chediak-
Higashi Syndrome). We also excluded prevalent secondary 
causes as HIV infection, leukaemia and diabetes mellitus. 
This case stresses the importance of  thinking of  cryptococcal 
meningitis in the differential diagnosis of  a child who is 
otherwise immunocompetent presenting with chronic 
headache, fever and meningeal signs. As we were not able 
to identify the Cryptococcus species in our patient, there is a 
possibility C. gattii would still be the causative agent, which 
has been increasingly reported as involved in severe CNS 
manifestations and classically has been described to affect 
immunocompetent individuals6. In addition to challenges in 
diagnosis, this case demonstrates the challenges of  providing 
care in resource-limited settings like Malawi where there is 
limited availability of  standard pharmacological agents, 
and where standard treatment of  cryptococcal meningitis 
is fluconazole monotherapy, which is a fungistatic drug7. 
Best treatment for cryptococcal meningitis in resource-
limited settings is combination therapy with fluconazole 
and amphotericin B,8 a fungicidal drug. However, even at a 
major referral centre such as ours, there is a lack of  effective 
first-line fungicidal drugs available, and hence only high-dose 
fluconazole was administered. 
In conclusion, diagnosis and treatment of  Cryptococcal 
infection in low resource settings continues to be a challenge 
and clearly affects the outcome of  patients. There is an 
urgent need to advocate for wide availability of  standard and 
effective fungicidal treatment in low resource settings world-
wide so as to reduce morbidity and mortality associated with 
cryptococcal meningitis. 
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Figure 1. Axial image of MRI brain of patient, illustrating mild 
hydrocephalus
